Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
BORCS8-MEF2B readthrough is a hybrid transcript formed from transcriptional continuity between the BORCS8 and MEF2B gene loci. While most of its transcripts are predicted to be non-coding due to nonsense-mediated decay, some can translate into a MEF2B isoform, which can function as a transcription factor involved in muscle gene regulation and possibly nervous system development. Clinical associations are limited, though MEF2B alterations (not explicitly readthrough variants) have been linked to neurodegeneration and certain lymphomas. The readthrough gene itself is not commonly recognized as a druggable therapeutic target or receptor[1][2][3][7][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on BORCS8-MEF2B readthrough (BORCS8-MEF2B).